Warning: getimagesize(/home/isofolme/public_html/wp-content/uploadshttps://www.pharmasalmanac.com/hubfs/2236109/PA_logo_Hoz_2019.svg): failed to open stream: No such file or directory in /home/isofolme/public_html/wp-content/themes/joyn/includes/plugins/aq_resizer-1x.php on line 80
Interviewed made by Redeye
Redeye has interviewed Ulf Jungnelius, CEO of Isofol, regarding the announcement that the AGENT study will be completed with 440…
by Admin IsofolThe abstract for AACR 2021 has been published
The approved abstract for the congress American Association for Cancer Research (AACR) 2021 has been published on their website. The…
by Admin IsofolIsofol announces that an abstract has been approved for AACR in April 2021
Isofol announces that an abstract has been approved for presentation at the virtual American Association for Cancer Research (AACR) Congress…
by Admin IsofolIsofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study
GOTHENBURG, Sweden, January 15, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that…
by Admin IsofolIsofol reaches 440 patients in global Phase III AGENT study
GOTHENBURG, Sweden, December 9, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that…
by Admin IsofolIsofol presents an abstract at ASCO GI in January 2021
Isofol announces that an abstract, including arfolitixorin in the ISO-CC-005 study, has been accepted to be presented at ASCO GI…
by Admin IsofolArfolitixorin is presented as one of the most promising pipeline drugs in the new CRC report by Global Data
Global Data recently published an outlook for the CRC market between 2018 and 2028 for the 8 major markets (8MM),…
by Admin IsofolEmpowered patient podcast
Our CEO, Dr. Ulf Jungnelius, was featured on Karen Jagoda’s empowered patient podcast to discuss colorectal cancer and how our…
by Admin IsofolPresentation and poster at ASCO Gastrointestinal Cancers Symposium
Isofol is attending the event and will present details in the ongoing global Phase 3 AGENT clinical study (ISO-CC-007) Presentation…
by Admin IsofolPharma’s Almanac – Round table
Our CEO, Anders Rabbe, was featured twice in Pharma’s Almanac Q3 issue in its “Round table” segment. He discussed the…
by Admin IsofolPublished abstract at ESMO
Published abstract at ESMO “Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-6 for first-line treatment of metastatic…
by Admin IsofolPoadcast – “The Cancer Gene”
Listen to recent episode from The Cancer Gene podcast features Anders Rabbe, CEO of Isofol, discussing colorectal cancer and the…
by Admin Isofolaside
Isofol has participated in the Empowered Patient Podcast
In honor of World Cancer Day on February 4, we would like to share a podcast where Anders Rabbe, CEO…
by Admin Isofol0aside
Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors
GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the appointment of…
by Admin Isofolaside
Isofol presents a poster at ESMO 2018 Congress in Germany
Isofol is attending the ESMO 2018 Congress in Germany, which is taking place between October 19-23. During Sunday the poster, “ISO-CC-005;…
by Admin Isofolaside
Patent approved in the United States for Isofol’s drug candidate arfolitixorin
The patent now approved in the United States expires in 2037 and covers both the Active Pharmaceutical Ingredient (arfolitixorin hemisulfate),…
by Admin Isofol